Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Leukemia

Free Subscription Articles published in Eur J Immunol Retrieve available abstracts of 12 articles: HTML format

Single Articles

November 2020
1. BRANDL C, Angermuller S, Nitschke L
   Humanized CD22 transgenic mouse model for in vivo analysis of anti-CD22-based immunotherapy.
   Eur J Immunol. 2020;50:1834-1837.
   PubMed    
   
   
   May 2020
2. ZHAO XY, Jiang Q, Jiang H, Hu LJ, et al
   Expanded clinical-grade membrane-bound IL-21/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo.
   Eur J Immunol. 2020 May 1. doi: 10.1002/eji.201948375.
   PubMed     Abstract available
   
   
   March 2020
3. KAISER TK, Li H, Rossmann L, Reichardt SD, et al
   Glucocorticoids delivered by inorganic-organic hybrid nanoparticles mitigate acute graft-versus-host disease and sustain graft-versus-leukemia activity.
   Eur J Immunol. 2020 Mar 4. doi: 10.1002/eji.201948464.
   PubMed     Abstract available
   
   
   November 2019
4. SWATLER J, Dudka W, Bugajski L, Brewinska-Olchowik M, et al
   Chronic myeloid leukemia-derived extracellular vesicles increase Foxp3 level and suppressive activity of thymic regulatory T cells.
   Eur J Immunol. 2019 Nov 23. doi: 10.1002/eji.201848051.
   PubMed    
   
   
   March 2019
5. AMES PR, Merashli M, Gentile F
   Rituximab/Bendamustine treatment of chronic lymphatic leukemia leads to sustained remission of antiphospholipid antibodies.
   Eur J Immunol. 2019 Mar 20. doi: 10.1002/eji.201848042.
   PubMed    
   
   
   November 2018
6. WEHRSTEDT S, Kubis J, Zimmermann A, Bruns H, et al
   The tyrosine kinase inhibitor dasatinib reduces the growth of intracellular Mycobacterium tuberculosis despite impairing T-cell function.
   Eur J Immunol. 2018;48:1892-1903.
   PubMed     Abstract available
   
   
   October 2018
7. URI A, Luhder F, Kerkau T, Beyersdorf N, et al
   During acute Graft versus Host Disease CD28 deletion in donor CD8(+) , but not CD4(+) , T cells maintains anti-leukemia responses in mice.
   Eur J Immunol. 2018 Oct 15. doi: 10.1002/eji.201847669.
   PubMed     Abstract available
   
   
   September 2018
8. GRUNBERG M, Quandt D, Cynis H, Demuth HU, et al
   Kallikrein-related peptidases are activators of the CC chemokine CCL14.
   Eur J Immunol. 2018;48:1592-1594.
   PubMed     Abstract available
   
   
   July 2018
9. ZOU Y, Luo W, Guo J, Luo Q, et al
   NK cell-mediated anti-leukemia cytotoxicity is enhanced using a NKG2D ligand MICA and anti-CD20 scfv chimeric protein.
   Eur J Immunol. 2018 Jul 31. doi: 10.1002/eji.201847550.
   PubMed     Abstract available
   
   
   May 2018
10. MATKO S, Manderla J, Bonsack M, Schmitz M, et al
    PRAME peptide-specific CD8(+) T cells represent the predominant response against leukemia-associated antigens (LAAs) in healthy individuals.
    Eur J Immunol. 2018 May 8. doi: 10.1002/eji.201747399.
    PubMed     Abstract available
    
    
    April 2018
11. SONG Y, Hu B, Liu Y, Jin Z, et al
    IL-12/IL-18-preactivated donor NK cells enhance GVL effects and mitigate GvHD after allogeneic hematopoietic stem cell transplantation.
    Eur J Immunol. 2018;48:670-682.
    PubMed     Abstract available
    
    
    February 2018
12. EWEN EM, Pahl JHW, Miller M, Watzl C, et al
    KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells.
    Eur J Immunol. 2018;48:355-365.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: